Driven by a number of favorable policies, individual stocks in the pharmaceutical sector have frequently risen and stopped

【Pharmaceutical Network Pharmaceutical Stock Market】On October 17, 2022, the pharmaceutical sector continued the overall general rally at the close of last week
.
Tongce Medical, Hengrui Pharmaceutical, Mindray Medical, etc.
all increased
by different magnitudes.
In addition, the data shows that on October 17, the A-share medical device sector index rose by more than 2.
35%, and Huitai Medical, Dirui Medical, Microelectrophysiology and other 20% up and down
.
Antu Biotechnology, Dabo Medical, Jiuan Medical, etc.
10% up and down
.
It is reported that on October 14, that is, from last Friday, the pharmaceutical sector as a whole rose sharply, and as of the close of the day, the pharmaceutical and biological sector rose 7.
13%; Medical devices and medical services both increased by more than 9%; From the perspective of individual stocks, Tongce Medical, Hengrui Medical, Changchun High-tech and so on have risen and stopped
.
The industry said that for the rise of the pharmaceutical sector, there are multiple favorable policies behind
it.
Among them, Zhongtai Securities said that multiple policies have released positive signals and are optimistic about the continuation of the
pharmaceutical and medical rebound.
After more than a year of full adjustment in the pharmaceutical sector, the overallocation ratio of institutional funds and industry valuation have returned to the bottom of
the ten-year cycle.
Recently, the pharmaceutical sector ushered in the gentle landing of spine centralized procurement, biochemical diagnostic reagents + electrophysiological consumables centralized procurement is better than expected, medical equipment subsidized loan encouragement policy, the medical insurance bureau reiterated that innovative medical devices will not be centralized procurement for the time being, and other multiple catalysts, long-term policy risks to suppress the valuation of the sector are expected to be gradually released, related sectors and individual stocks are expected to come out of the trough of performance, and investment sentiment is expected to continue to improve
.
Southwest Securities said that the recent policy side has released positive signals, and the sector sentiment has improved
positively.
If the pharmaceutical policy is again favorable, on October 14, Jiangxi's "Document on Centralized Procurement of Liver Function and Biochemical Testing Reagents Inter-provincial Alliance (Draft for Comments)" flowed out, the basic principle of this program is similar to the plan of orthopedic national procurement, and the overall rules are more moderate, exceeding market expectations, which is expected to drive the valuation of the IVD sector to repair; On October 12, the National Medical Insurance Administration said that it had included new indications in the scope of simple renewal consideration, and the price reduction ratio of simple renewal products was relatively loose, and the declaration process was significantly simplified, which brought more benefits
to the medical insurance access of new indications with little impact on medical insurance funds and relatively small number of patients.
Combined with the previous events: 1) the landing of the spine centralized procurement is moderate, 2) the medical insurance bureau stated that innovative equipment will not be collected for the time being, 3) the health commission issued a financial subsidized loan to protect the hospital equipment procurement funds, 4) medical services on the price of dental implants exceeded expectations, the market's confidence in the pharmaceutical sector has improved significantly, and the valuation of the sector has ushered in a recovery
.
Analysts pointed out that the superposition of a series of favorable policies has greatly boosted the confidence of pharmaceutical industry practitioners, and the upward trend is expected to continue until early next year
.
It is understood that while the stock price of the pharmaceutical sector has risen sharply, the three quarterly reports or performance forecasts recently disclosed have also sent positive signals
to the market.
For example, on the evening of October 17, Bede Pharma issued an announcement that it is expected that the company's operating income in the first three quarters will increase by 38% year-on-year to 589 million yuan, and the non-net profit will increase by 46.
5% year-on-year to 95.
81 million yuan
.
The company said that the market demand for its drug molecular building blocks and scientific reagents segment is strong, which promotes the rapid growth of
performance.
Wantai Biotech also issued an announcement on the evening of October 17, showing that its operating income in the first three quarters increased by 140.
6% year-on-year to 8.
65 billion yuan, and its non-net profit increased by 233% year-on-year to 3.
85 billion yuan
.
The increase was mainly due to higher
revenue from bivalent cervical vaccines, reagents and active raw materials.
In addition, Xiangsheng Medical, WuXi AppTec, China Resources Sanjiu and other companies have also disclosed their third-quarter performance forecasts, and their performance has achieved positive growth
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.